DANAHER CORPORATION

2017 OVERVIEW
 Forward Looking Statements
Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are
"forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business
decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.
These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, contractions or growth rates and cyclicality of
markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our
employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to
effectively address cost reductions and other changes in the health care industry, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully
complete divestitures and other dispositions, our ability to integrate the recent acquisitions of Pall Corporation and Cepheid and achieve the anticipated benefits of such transactions,
contingent liabilities relating to acquisitions and divestitures (including tax-related and other contingent liabilities relating to the distributions of each of Fortive Corporation and our
communications business), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on
our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities,
changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights
of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects,
product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our
channel partners, uncertainties relating to collaboration arrangements with third parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to
reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal,
compliance and business factors (including the impact of the UK's decision to leave the EU), disruptions relating to man-made and natural disasters, and pension plan costs. Additional
information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2017 Annual Report
on Form 10-K. These forward-looking statements speak only as of the date of this presentation and except to the extent required by applicable law, the Company does not assume any
obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

With respect to the non-GAAP financial measures referenced in the following presentation, the accompanying information required by SEC Regulation G can be found in the back of the
presentation. All references in this presentation (1) to company-specific financial metrics relate only to the continuing operations of Danaher’s business, unless otherwise noted; (2) to
“growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated; (3) to Operating Profit below the segment level exclude amortization; and (4)
to “today” refers to the Company’s 2017 performance. We may also describe certain products and devices which have applications submitted and pending for certain regulatory
approvals.

2
 2017 Financial Highlights
CORE REVENUE GROWTH ACCELERATION THROUGH THE YEAR
• Life Sciences, Diagnostics and Environmental & Applied Solutions all 4% core revenue growth
in 2017
• Overall Danaher core revenue growth of 5.5% in Q4 2017

DOUBLE-DIGIT FREE CASH FLOW & ADJUSTED EPS GROWTH

• FCF exceeded Net Income for 26th consecutive year

EXPANDING MARGINS WHILE REINVESTING FOR GROWTH

• Core OMX +70bps, R&D up/G&A down (as a % of sales)

RECENT ACQUISITIONS OFF TO A GREAT START

• Cepheid, Pall, Nobel all performing well
• Closed 10 deals for ~$400M of acquisition spend
All financial metrics based on FY 2017 Building momentum as we begin 2018
3
 Danaher Today
LIFE
DIAGNOSTICS ~$5.8B ~$5.7B ENVIRONMENTAL & APPLIED SOLUTIONS ~$4.0B DENTAL ~$2.8B
SCIENCES
WATER QUALITY PRODUCT ID

All financial metrics shown reflect FY 2017 revenues

Multi-industry science & technology portfolio provides competitive advantages

4
 Evolution of Danaher
~$90M REVENUE ~$4B REVENUE ~$18B REVENUE

Today
1984

2000
~20% GROSS MARGIN <40% GROSS MARGIN ~55% GROSS MARGIN
-- CONSUMABLES REV. <15% CONSUMABLES REV. ~65% CONSUMABLES REV.
-- HGM REVENUE <10% HGM REVENUE ~30% HGM
Founded by
Steve & Mitch Rales OPCOS AQUIRED SINCE OF DANAHER TOTAL
2011 REPRESENT >50% REVENUE TODAY
~$18B
KEY ACQUISITIONS & PORTFOLIO MOVES

~$9B

TOOLS JV COMMS RMT SPIN

Shaded area represents 2017 revenue for each OpCo

Significant portfolio transformation creates significant opportunity

5
 Revenue
By Mix

STRONG PORTFOLIO
Equipment
35%
~$18B TOTAL
REVENUE

UNITED BY COMMON Consumables

BUSINESS MODEL 65%

~55% GROSS
MARGIN

By Geography
• Outstanding brands with market-
>20%
ADJUSTED
ROW
leading positions 6%
EBITDA
MARGIN
NA
HGM
40%
30%
• Extensive installed base
>100%
EU FREE CASH
24% FLOW TO
NET INCOME
• Strong ‘captive’ recurring revenues
Direct vs. Distribution
Building & enhancing a
• High level of customer intimacy Distribution
30%
Direct
sustainable growth, earnings
All financial metrics based on FY 2017 and all pie chart percentages are % of 2017 revenues
70%
and free cash flow profile
6
 Well-Positioned Portfolio Serving Attractive End-Markets

LIFE SCIENCES DIAGNOSTICS WATER QUALITY PRODUCT ID DENTAL

ADDRESSABLE MARKET SIZE ~$40B ~$35B ~$20B ~$10B ~$20B

REGULATORY REQUIREMENTS

WORKFLOW EFFICIENCY

HIGH GROWTH MARKETS

IMPROVING STANDARDS OF CARE

ENVIRONMENTAL SAFETY

Attractive end-markets with strong secular drivers and higher barriers to entry
7
 Danaher Business System (DBS)

8
 20 Year Total Shareholder Return: DHR vs S&P 500
DHR 1500%
Years DHR S&P 500 Difference

3 Year 46% 38% 8%

10 Year 189% 126% 63%
1000%
20 Year 1,529% 301% 1,228%

500%

S&P 500

0%
Dec-97 Dec-99 Dec-01 Dec-03 Dec-05 Dec-07 Dec-09 Dec-11 Dec-13 Dec-15 Dec-17

Outperforming over the long term

9
 Our Strategic Priorities

Strengthen our competitive advantage with DBS

Enhance our portfolio via strategic M&A

Attract & retain exceptional talent

10
 DBS Is Our Competitive Advantage
8 CORE VALUE DRIVERS
CORE REVENUE GROWTH
OMX
SHAREHOLDER
Leadership CASH FLOW / WC TURNS
ROIC

QUALITY (EXTERNAL PPM)

CUSTOMER ON-TIME DELIVERY (OTD)
Lean Growth
INTERNAL FILL RATE
ASSOCIATE RETENTION

“OMX” is Operating Margin Expansion; “WC” is Working Capital

“Common sense vigorously applied”
11
 Evolution of the Danaher Business System (DBS)

1984 1991 1999 2001 2003 2005 2007 2009 2011 2013 2015 TODAY
2017E

Leadership
Leadership Leadership Leadership

Lean Growth Lean Growth Lean Growth

2016 Lean Growth
LAUNCHED
2009 SHARED
2001 ADDED PURPOSE
Mid-1980s LEADERSHIP OUR SHARED PURPOSE
ADDED
HELPING REALIZE LIFE’S POTENTIAL
LEAN GROWTH
FOCUSED

As portfolio evolved, so has DBS – from Lean to a balanced approach

12
 How We Create Value: Running the Danaher Playbook

Core Revenue Growth

IMPROVE COST Gross

G&A
+
Margins Margin Expansion
STRUCTURE

REINVEST
+
R&D S&M Strong Free Cash Flow
FOR GROWTH
+
ACCELERATE Acquisitions
Core
MARGINS & OMX
CORE GROWTH
Growth =
TOP QUARTILE EPS GROWTH &
COMPOUNDING RETURNS

Balanced approach to deliver long-term value to shareholders

13
 Historical Performance
$18.3B
$16.9B
TOTAL $14.4B $4.03
REVENUE $12.9B
$3.61

ADJUSTED EPS $2.98

$2.66

2014 2015 2016 2017

Mid-teens adjusted EPS CAGR from 2014 – 2017

14
 Superior Free Cash Flow Generation

$2.9B
$2.5B

$2.4B
$2.2B
TOTAL FCF

FCF/NET INCOME
CONVERSION RATIO 135% 136%
116% 117%

2014 2015 2016 2017

2017 free cash flow exceeded net income for 26th year in a row
15
 Our Strategic Approach to M&A

MARKET

• Secular growth drivers COMPANY

• Fragmented
• Higher barriers to entry • Competitive market position VALUATION
• Optionality with multi-industry • Strong brand / channel
portfolio • Consistent revenue visibility • Focus on ROIC
• Higher margin businesses • DBS opportunities
• Cultural fit • Sustainability
• Synergies with DHR OpCos
• Combination of value & growth deals

“ROIC” is Return on Invested Capital Selectively pursuing value creation opportunities

16
 Value Creation Model: Videojet Example

CORE REVENUE

MSD CAGR OVER THE

LAST 8 YEARS
VIDEOJET
ROIC (%)
>100BPS
AVG. ANNUAL
OMX LAST 3
YEARS

Comprint
(Brazil)
EWA
BIS
(Poland)
F. Armida
(Mexico)
Echter +
Konig SA
(Argentina)
Vega
(Brazil)
14 ACQUISITIONS
SINCE 2002

>20%
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
ROIC
TODAY
CORE GROWTH CAGR LSD CORE GROWTH CAGR MSD

Organic execution + M&A = compounding returns

17
 Update on Recent Larger Acquisitions

ACQUIRED DEC 2014 3 YEARS IN ACQUIRED AUG 2015 2 YEARS IN ACQUIRED NOV 2016 1 YEAR IN
AT ACQ. TODAY AT ACQ. TODAY AT ACQ. TODAY

Core Growth Flat/LSD MSD Core Growth LSD MSD* Core Growth DD DD

Gross Margin ~70% >70% Gross Margin ~50% >50% Gross Margin ~50% ~55%
Operating Operating High- Operating Mid-
Profit Margin LDD >20% Profit Margin ~25% Profit Margin Flat/LSD
teens teens
ROIC LSD  HSD ROIC LSD  MSD ROIC —  LSD

*Reflects 2H 2017
Deals at or above initial expectations
18
 Evolving Strategic Approach to Talent
TALENT 10+ YEARS AGO TODAY

• General industrial talent • Science & technology talent

• Outsourced talent acquisition • Internal talent acquisition & cultivation
ORGANIZATION

• OpCos & Corporate • Platform leadership driving strategic moves

& portfolio evolution
DEVELOPING LEADERS • OpCos execute strategic decisions

• Development primarily “on the job” • Progressive responsibilities & formalized

development programs

Associates are key to sustaining our competitive advantage

19
 Revenue
By Mix

DIAGNOSTICS Equipment
15%

Consumables
85%
~$5.8B REVENUE

By Geography

~25%
ADJUSTED
ROW EBITDA
6% MARGIN
NA
HGM 39%
36%
EU 19%

By OpCo
~$35B ADDRESSABLE
MARKET SIZE
TAS HemoCue

Cepheid
Radiometer Beckman
Diagnostics
Strong brands with a broad
All financial metrics based on FY 2017 and all pie chart percentages are % of 2017 revenues
LBS global presence
20
 Revenue
By Mix

LIFE SCIENCES Equipment

~$5.7B
40%
Consumables REVENUE
60%

By Geography

~25%
ADJUSTED
ROW
EBITDA
10%
NA MARGIN
HGM
34%
27%
EU
29%

By End-Market
~$40B ADDRESSABLE
MARKET SIZE

Research
Industrial
Applied
Strong global brands with
Clinical Biopharma /
All financial metrics based on FY 2017 and all pie chart percentages are % of 2017 revenues Pharma leading market positions
21
ENVIRONMENTAL & APPLIED SOLUTIONS (EAS) Revenue
By Mix

WATER QUALITY Equipment

Consumables
60%
40%
~$2.2B REVENUE

By Geography

>25%
EAS ADJUSTED
EU EBITDA
18% MARGIN
NA
HGM 52%
27% ROW

~$20B
3%
ADDRESSABLE
MARKET SIZE
By End-Market

Env. /
Other
Muni

Industrial
A global leader in water
All financial metrics based on FY 2017 and all pie chart percentages are % of 2017 revenues measurement & treatment
22
ENVIRONMENTAL & APPLIED SOLUTIONS (EAS) Revenue
By Mix

PRODUCT ID Equipment

~$1.8B
45%
Consumables REVENUE
55%

By Geography

>25%
EAS ADJUSTED
EBITDA
EU MARGIN
NA
30%
30%
HGM ROW
36%

~$10B
4%
ADDRESSABLE
MARKET SIZE
By End-Market

CPG Food
& Bev
Industrial
Leading global player supporting
All financial metrics based on FY 2017 and all pie chart percentages are % of 2017 revenues Other
Pharma
the entire packaging value chain
CPG
23
 Revenue
By Mix

DENTAL Traditional
Specialty Consum.
Consum.
(implants, ortho)
Equipment
~$2.8B REVENUE

By Geography
High- ADJUSTED
EBITDA

teens
HGM MARGIN
EU 23%
22%
ROW
6%
NA

~$20B
49%
ADDRESSABLE
MARKET SIZE
Direct vs. Distribution

Distribution Direct A leading global player

All financial metrics based on FY 2017 and all pie chart percentages are % of 2017 revenues covering entire dental workflow
24
 Non-GAAP Reconciliations
Adjusted EBITDA Margins
($ in Millions)

Year Ended December 31, 2017

Corporate Total
Life Sciences Diagnostics Dental EAS
Office Danaher
Operating Profit (GAAP) $ 1,004.3 $ 871.6 $ 400.7 $ 914.6 $ (170.0) $ 3,021.2
Depreciation 119.0 368.1 39.7 43.4 7.6 577.8
Amortization 308.9 213.4 81.7 56.5 0.0 660.5
Segment EBITDA (Non-GAAP) $ 1,432.2 $ 1,453.1 $ 522.1 $ 1,014.5 $ (162.4) $ 4,259.5
Interest, net (155.2)
Other Income 72.8
Income Taxes (469.0)
Depreciation (577.8)
Amortization (660.5)
Net Income Continuing Ops (GAAP) $ 2,469.8

Net Sales $ 5,710.1 $ 5,839.9 $ 2,810.9 $ 3,968.8 $ 18,329.7

Segment EBITDA Margin (Non-GAAP) ≈25% ≈25% High-teens >25% >20%

(1) Management defines "Segment EBITDA" as GAAP operating income excluding (1) depreciation and (2) amortization, and defines
26 "Segment EBITDA Margin" as Segment EBITDA divided by sales.
 Non-GAAP Reconciliations
Reconciliation of Operating Cash Flows from Continuing Operations (GAAP) to Free Cash Flow from Continuing Operations (Non-GAAP)
($ in Millions)

Full Year Ended December 31

Free Cash Flow from Continuing Operations: 2014 2015 2016 2017

Operating Cash Flows from Continuing Operations (GAAP) $ 2,671.2 $ 2,832.2 $ 3,087.5 $ 3,477.8

Less: purchases of property, plant & equipment (capital expenditures) from continuing operations
(GAAP) (465.4) (512.9) (589.6) (619.6)
Plus: proceeds from sale of property, plant & equipment (capital disposals) from continuing
operations (GAAP) 4.2 60.4 9.8 32.6

Free Cash Flow from Continuing Operations (Non-GAAP) $ 2,210.0 $ 2,379.7 $ 2,507.7 $ 2,890.8

Ratio of Free Cash Flow to Net Earnings from Continuing Operations:

Free Cash Flow from Continuing Operations from Above (Non-GAAP) $ 2,210.0 $ 2,379.7 $ 2,507.7 $ 2,890.8

Net Earnings from Continuing Operations (GAAP) 1,638.7 1,746.7 2,153.4 2,469.8

Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations
Conversion Ratio (Non-GAAP) 1.35 1.36 1.16 1.17

We define free cash flow as operating cash flows from continuing operations, less payments for purchases of property, plant and equipment from continuing operations (“capital expenditures”) plus
the proceeds from the sale of plant, property and equipment from continuing operations (“capital disposals”).

27
 Revenue Performance

Non-GAAP Reconciliations
Year-Over-Year Core Operating Margin Changes
Three-Month Period
Ended December 31

Total Danaher
Year Ended December 31, 2017

Life Sciences Diagnostics Dental EAS

Total
Danaher

Segments
Total Revenue Growth from Continuing Operations (GAAP) 11.0% 6.5% 16.0% 1.0% 7.5% 8.5%
Environmental
Total and Applied Less the impact of:
Company Life Sciences Diagnostics Dental Solutions
Acquisitions and other (2.5%) (2.0%) (12.0%) 0.0% (3.0%) (4.5%)
Three-Month Period Ended December 31, 2016 Operating Currency exchange rates (3.0%) (0.5%) 0.0% (1.0%) (0.5%) (0.5%)
Profit Margins from Continuing Operations (GAAP)
15.90% 16.80% 12.60% 15.40% 24.00% 1
Core Revenue Growth from Continuing Operations (Non-GAAP) 5.5% 4.0% 4.0% 0.0% 4.0% 3.5%
Fourth quarter 2017 impact from operating profit margins of
businesses that have been owned for less than one year or 1 We use the term “core revenue” to refer to GAAP revenue from continuing operations excluding (1) sales from acquired businesses recorded prior to the first anniversary of the
were disposed of during such period and did not qualify as acquisition less the amount of sales attributable to divested businesses or product lines not considered discontinued operations (“acquisition sales”) and (2) the impact of
discontinued operations (0.15) (0.10) (0.40) - (0.40) currency translation. The portion of GAAP revenue from continuing operations attributable to currency translation is calculated as the difference between (a) the period-to-
Tradename impairments and related restructuring in the period change in revenue (excluding acquisition sales) and (b) the period-to-period change in revenue (excluding acquisition sales) after applying current period foreign
Dental segment (0.20) - - (1.30) - exchange rates to the prior year period. We use the term “core revenue growth” to refer to the measure of comparing current period core revenue with the corresponding period
Fourth quarter 2017 gain (loss) on resolution of acquisition- of the prior year.
related matters
0.20 (0.20) 0.90 - -
Acquisition-related transaction costs deemed significant,
change in control payments and restructuring charges, and fair
value adjustments to inventory and deferred revenue, in each
case primarily related to the acquisitions of Cepheid &
Phenomenex and incurred in the fourth quarter of 2016. 1.80 0.45 5.35 - -
Adjusted Diluted Net Earnings Per Share from Continuing Operations
Year-over-year core operating profit margin changes for
fourth quarter 2017 (defined as all year-over-year operating
profit margin changes other than the changes identified in the
line items above) (non-GAAP) Full Year Ended December 31
1.05 3.05 1.05 (1.00) (0.50)
2014 2015 2016 2017
Three-Month Period Ended December 31, 2017 Operating
Profit Margins from Continuing Operations (GAAP) 18.60% 20.00% 19.50% 13.10% 23.10%
Diluted Net Earnings Per Share from Continuing Operations (GAAP) $ 2.29 $ 2.47 $ 3.08 $ 3.50
Year Ended December 31, 2016 Operating Profit Margins
from Continuing Operations (GAAP) 16.30% 15.30% 15.60% 15.10% 23.60% A A A A A
Pretax amortization of acquisition-related intangible assets 0.38 0.56 0.83 0.94
Full year 2017 impact from operating profit margins of
B,C B C
businesses that have been owned for less than one year or Pretax gains on resolution of acquisition-related matters - - (0.02) (0.02)
were disposed of during such period and did not qualify as D,E,F,G D E F G
discontinued operations Pretax gain on sales of investments (0.17) (0.02) (0.32) (0.10)
(0.50) 0.20 (1.50) (0.10) (0.65)
Tradename impairments and related restructuring in the Pretax productivity charges in excess of amounts originally budgeted H
H -
Dental segment (0.05) - - (0.35) - and publicly communicated in December 2013 0.09 - -
Acquisition-related transaction costs deemed significant, Pretax restructuring, impairment and other related charges recorded in I
change in control payments and restructuring charges, and fair the second quarter of 2017
I
value adjustments to inventory and deferred revenue, in each
- - - 0.11
J J
case primarily related to the acquisitions of Cepheid & Pretax charge for early extinguishment of borrowings - - 0.26 -
Phenomenex and incurred in the fourth quarter of 2016.
0.50 0.10 1.50 - - Pretax acquisition-related transaction costs deemed significant, change
Third quarter 2016 (gain) and fourth quarter 2017 gain (loss) in control payments and restructuring costs and fair value adjustments
on resolution of acquisition-related matters (0.05) (0.05) 0.25 - - K,L,M
to inventory and deferred revenue 0.02 K
0.21 K,L
0.12 M
-
Full year 2017 impact of restructuring, impairment and
related charges related to the discontinuation of a product Tax effect of all adjustments reflected above N (0.04) N
(0.16) N
(0.21) N
(0.19) N
line in the Diagnostics segment in the second quarter of 2017 (0.40) - (1.30) - - O,P,Q,R O P Q R
Discrete tax adjustments and other tax-related adjustments 0.09 (0.08) (0.13) (0.21)
Year-over-year core operating profit margin changes for full
year 2017 (defined as all year-over-year operating profit
margin changes other than the changes identified in the line Adjusted Diluted Net Earnings Per Share from Continuing Operations
$ 2.66 $ 2.98 $ 3.61 $ 4.03
items above) (non-GAAP) (Non-GAAP)
0.70 2.05 0.35 (0.35) 0.05
28 Year Ended December 31, 2017 Operating Profit Margins
from Continuing Operations (GAAP) 16.50% 17.60% 14.90% 14.30% 23.00%
 Q Discrete income tax gains net of discrete income tax charges and Fortive separation-related tax costs related to repatriation of earnings and legal entity realignments
incurred in the year ended December 31, 2016 ($91 million).
R Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2017 include:

Non-GAAP Reconciliations
A Amortization of acquisition-related intangible assets in the following periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line
($ in millions)
Discrete income tax gains, primarily related to expiration of statute of limitations 1
$
Year Ended
December 31,
2017

129
2
Impact of ASU No. 2016-09, Compensation—Stock Compensation
item above): 16
3
Remeasurement of deferred tax assets and liabilities as a result of the Tax Cuts and Jobs Act of 2017
1,219
Year Ended December 31 Transition tax on deemed repatriation of foreign earnings as a result of the Tax Cuts and Jobs Act of 2017 4
(1,218)
2014 2015 2016 2017
$ 146
Pretax $ 269.2 396.7 $ 583.1 $ 660.5
After-tax 215.3 449.7 523.5 Represents (1) discrete income tax gains, primarily related to expiration of statute of limitations ($129 million in the year ended December 31, 2017), (2) equity
313.4
compensation-related excess tax benefits ($16 million in the year ended December 31, 2017), (3) remeasurement of deferred tax assets and liabilities, net related to
enactment of the Tax Cuts and Jobs Act ($1.2 billion gain in the year ended December 31, 2017), and (4) transition tax on deemed repatriation of foreign earnings in
B Gains on resolution of acquisition-related matters ($18 million pretax as presented in this line item, $14 million after-tax) for the year ended December 31, 2016. connection with enactment of the Tax Cuts and Jobs Act ($1.2 billion provision in the year ended December 31, 2017).

C Net gains on resolution of acquisition-related matters in the Life Sciences and Diagnostics segments ($11 million pretax as presented in this line item, $8 million after- On January 1, 2017, Danaher adopted the updated accounting guidance required by ASU No. 2016-09, Compensation—Stock Compensation , which requires income
tax) for the year ended December 31, 2017. statement recognition of all excess tax benefits and deficiencies related to equity compensation. We exclude from Adjusted Diluted Net EPS any excess tax benefits
that exceed the levels we believe are representative of historical experience. In the first quarter of 2017, we anticipated $10 million of equity compensation-related
D Gain on sale of marketable equity securities in the year ended December 31, 2014 ($123 million pretax as presented in this line item, $77 million after-tax). excess tax benefits and realized $26 million of excess tax benefits, and therefore we have excluded $16 million of these benefits in the calculation of Adjusted Diluted
Net Earnings per Share. In the second, third and fourth quarters of 2017, realized equity compensation-related excess tax benefits approximated the anticipated benefit
E Gain on sale of marketable equity securities in the year ended December 31, 2015 ($12 million pretax as presented in this line item, $8 million after-tax). and no adjustments were required.
F Gain on sales of investments in the year ended December 31, 2016 ($223 million pretax as presented in this line item, $140 million after-tax). Statement Regarding Non-GAAP Measures
G Gain on sales of investments in the year ended December 31, 2017 ($73 million pretax as presented in this line item, $46 million after-tax). Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the
comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that
H Continuing operations portion of productivity charges for the year ended December 31, 2014 in excess of amounts originally budgeted and publicly communicated in these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the
December 2013 ($64 million pretax as presented in this line item, $49 million after-tax). “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors to:

I During the year ended December 31, 2017, the Company recorded $76 million of pretax restructuring, impairment and other related charges ($51 million after-tax) • with respect to Adjusted Diluted Net EPS, understand the long-term profitability trends of our business and compare our
profitability to prior and future periods and to our peers; and
primarily related to the Company’s strategic decision to discontinue a molecular diagnostic product line in its Diagnostics segment. As a result, the Company incurred
noncash charges for the impairment of certain technology-related intangibles as well as related inventory and plant, property and equipment with no further use totaling • with respect to core revenue, identify underlying growth trends in our business and compare our revenue performance with
$49 million. In addition, the Company incurred cash restructuring costs primarily related to employee severance and related charges totaling $27 million. prior and future periods and to our peers.

J Charge for early extinguishment of borrowings ($179 million pretax as presented in this line item, $112 million after-tax) incurred in the third quarter of 2016. Management uses these non-GAAP measures to measure the Company’s operating and financial performance, and uses a non-GAAP measure
similar to Adjusted Diluted Net EPS in the Company’s executive compensation program.
K Acquisition-related transaction costs deemed significant ($12 million pretax as presented in this line item, $9 million after-tax) for the year ended December 31,
The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
2014 and fair value adjustments to inventory ($5 million pretax as presented in this line item, $4 million after-tax) for the year ended December 31, 2014 and fair
value adjustments to inventory ($20 million pretax as presented in this line item, $15 million after-tax) incurred in the year ended December 31, 2015, in each case • With respect to Adjusted Diluted Net EPS:
incurred in connection with the acquisition of Nobel Biocare. Danaher deems acquisition-related transaction costs incurred in a given period to be significant
o We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges
(generally relating to Danaher’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have
a given period. a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an
acquisition’s purchase price allocated to intangible assets and related amortization term are unique to each acquisition
L Acquisition-related transaction costs deemed significant ($21 million pretax as presented in this line item, $16 million after-tax), change in control payments, and fair and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more
consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with
value adjustments to inventory and deferred revenue, net of the impact of freezing pension benefits, in each case related to the acquisition of Pall Corporation and both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to
incurred in the year ended December 31, 2015 ($107 million pretax as presented in this line item, $84 million after-tax) understand that such intangible assets contribute to revenue generation and that intangible asset amortization related to
past acquisitions will recur in future periods until such intangible assets have been fully amortized.
M Acquisition-related transaction costs deemed significant ($12 million pretax as presented in this line item, $9 million after-tax), change in control payments and o We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the
restructuring costs ($49 million pretax as presented in this line item, $30 million after-tax), and fair value adjustments to inventory and deferred revenue ($23 million size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing
productivity improvements that result from application of the Danaher Business System. Because these restructuring
pretax as presented in this line item, $14 million after-tax), in each case related to the acquisitions of Cepheid and Phenomenex and incurred in the year ended
plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not
December 31, 2016. The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs from the calculation of
acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period. Adjusted Diluted Net EPS to facilitate a more consistent comparison of operating results over time.

o With respect to the other items excluded from Adjusted Diluted Net EPS, we exclude these items because they are of a
N This line item reflects the aggregate tax effect of all nontax adjustments reflected in the table above. In addition, the footnotes above indicate the after-tax amount of nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher’s
commercial performance during the period and/or we believe are not indicative of Danaher’s ongoing operating costs
each individual adjustment item. Danaher estimates the tax effect of the adjustment items identified in the reconciliation schedule above by applying Danaher’s overall or gains in a given period; we believe that such items may obscure underlying business trends and make comparisons
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a of long-term performance difficult.
specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. • With respect to core revenue, (1) we exclude the impact of currency translation because it is not under management’s
control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions a nd
O Discrete income tax charges net of discrete income tax gains and benefits from a lower than expected effective tax rate in the year ended December 31, 2014 divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-
(compared to the anticipated effective tax rate publicly communicated in December 2013), due primarily to year-end 2014 tax law changes period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of
long-term performance difficult.
Discrete income tax gains net of discrete income tax charges incurred in the year ended December 31, 2015 ($58 million).
29
P